Acute myeloid leukemia (AML) is a hematologic malignancy that most frequently develops in
older adults. Overall, AML is associated with a high mortality although advancements in …

The treatment landscape of acute myeloid leukaemia (AML) is evolving rapidly. Venetoclax
in combination with intensive chemotherapy or doublets or triplets with targeted or immune …

Chemotherapy-resistant acute myeloid leukemia (AML), frequently driven by clonal
evolution, has a dismal prognosis. A genome-wide CRISPR knockout screen investigating …

Simple Summary Today, the classification of acute myeloid leukemia is mainly based on
genetic aberrations found in leukemic cells. Classifying this disease is necessary for exact …

Abstract Relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) is a genetically complex
and heterogeneous disease with a poor prognosis and limited treatment options. Thus, there …

NGS has proven to be a useful approach for the analysis of genomic alterations in patients
with AML, which aids patient management. Current research is being directed at reducing …

Mutations found in AML such as DNMT3A, TET2 and ASXL1 can be found in the peripheral
blood of healthy adults-a phenomenon termed clonal hematopoiesis (CH). These mutations …

Next-generation sequencing is becoming increasingly important for the diagnosis, risk
stratification, and management of patients with established or suspected myeloid …

Background As we delve into the intricate world of venetoclax combination therapy in
relapsed or refractory acute myeloid leukemia (AML), our exploration not only aims to …

Many genetic markers are known to distinguish tumor cells from normal. Genetic lesions
found at disease onset often belong to a predominant tumor clone, and further observation …